Gastrointestinal Diseases and Disorders Clinical Trials
A listing of Gastrointestinal Diseases and Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 64 clinical trials
Eosinophilic Esophagitis Research Study
The purpose of this study is to see if CC-93538 is safe and effective as a possible treatment for EoE. To do this, a comparison will be made between subjects who receive CC-93538 and subjects who receive a placebo (a ‘dummy treatment’ that looks like CC-93538 but contains no active …
- 0 views
- 14 Jan, 2022
- 1 location
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)
- 237 views
- 23 Nov, 2020
- 1 location
A Phase 2b, Randomized, Doubl-blind, Placebo-controlled, Parallel-group, Dose-ranging-finding Trial of XXXXX Administered Orally for 8 Weeks to Patients with Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors
A Phase 2b, Randomized, Doubl-blind, Placebo-controlled, Parallel-group, Dose-ranging-finding Trial of XXXXX Administered Orally for 8 Weeks to Patients with Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors
- 1253 views
- 08 Nov, 2020
- 1 location
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
- 1167 views
- 25 Mar, 2021
- 1 location
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
- 446 views
- 25 Mar, 2021
- 1 location
Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (REVISE)
Patients who are critically ill in the in the Intensive Care Unit (ICU), especially those who need a breathing machine, can develop ulcers in the stomach that bleed. To prevent bleeding, many such patients around the world receive a drug called pantoprazole that decreases acid production. However, today, compared to …
- 509 views
- 11 Mar, 2022
- 53 locations
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI)
Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects from chemotherapy agents. Testing is not regularly performed in clinical practice due to long wait times for results and challenges with integrating test …
- 1 views
- 17 Oct, 2022
- 3 locations
Symptom Management Implementation of Patient Reported Outcomes in Oncology (SIMPRO)
Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care …
- 5 views
- 17 Feb, 2022
- 6 locations
A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers
Phase Ia - Explore safety and establish the maximum tolerated dose (MTD)/recommended dose levels for phase Ib expansion phase of BI 905711 based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period. The MTD evaluation period is defined as the first two treatment cycles …
- 76 views
- 20 Oct, 2022
- 14 locations
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations before and after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin …
- 9 views
- 22 Apr, 2021
- 1 location